Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 15, 2006

View Archived Issues

Third-generation anti-CD20 antibody shows promise for the treatment of B-cell lymphomas

Phase I/II data show activity of pralatrexate in peripheral T-cell lymphomas

Senicapoc safe, beneficial with long-term treatment in sickle cell disease

AKR-501 increases platelet counts in healthy subjects

Snapshots of recent clinical trials in glioma: Part II

In vitro efficacy of an anti-IGF-1R antibody, AVE-1642, in multiple myeloma

Helix studies topical interferon alpha-2b for anogenital warts

GSK and Epix establish GPCR collaboration

Indevus to acquire Valera

Bifeprunox NDA filed for review

Cell-mediated gene therapy studied for pulmonary arterial hypertension

Schwarz Pharma transfers urology R&D project to 4SC

Phase III study opens in U.S. for Grazax

Biofrontera advances phase IIb/III trial of BF-200 ALA in actinic keratosis

Anyara achieves proof of concept

Genmab announces fully human HuMax-ZP3 antibody program

European orphan drug designation for Sarcodoxome for soft tissue sarcoma

Lilly reviews pipeline progress

Novel treatment options for metabolic disorders described in recent patent literature

New agents for gastrointestinal disorders reported in recent patents

Merck & Co. reviews pipeline status

Biomira reaches SPA for phase III Stimuvax trial

Sanctura XR NDA accepted for review

Tykerb studied as adjuvant treatment in early-stage HER2-positive breast cancer

KRX-0401 begins phase II for rare sarcomas

MicroIslet holds pre-IND meeting for allotransplantation approach in diabetes

Phase II data support once-daily Gabapentin GR in diabetic peripheral neuropathy

Interim safety analysis findings from phase IIb telaprevir HCV study

PI-88 increases disease-free survival by 76% in hepatocellular cancer study

Antagonists of adrenomedullin may be useful to treat bone metastasis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...